Wednesday | 8 October, 2008
Stories by: Staff Writers
- +
Biotech briefs 29/09/2008 15:45:00
Molloy joins Viralytics - +
Next step for Xenome 25/09/2008 11:40:00
Xenome starts Phase II for acute post-operative pain - +
Vaccines and the world 12/09/2008 12:50:00
The World Vaccines Congress is coming to Sydney next month - +
Next trial for Starpharma 13/08/2008 15:19:56
Starpharma studies VivaGel duration - +
NSW-Korea grants program 07/08/2008 16:34:26
Collaboration grants open for NSW-Gangwon technology projects - +
Pond scum and the biofuel revolution 29/07/2008 16:40:47
Murdoch Uni wins grant to research turning algae into energy - +
Combination therapy for HIV 25/07/2008 16:31:51
Merck drug raltegravir shows good results as part of combination therapy - +
IP Australia sits US exams 25/07/2008 16:49:04
IP Australia named as search and examination authority for US patent office - +
Cash for medical research support 25/07/2008 16:19:07
The NHMRC has announced $29 million for medical research institute support services - +
Pfizer Fellowships close soon 23/07/2008 12:40:24
Applications for the Pfizer Australia Research Fellowships close on Monday - +
Biotech summit approaches 23/07/2008 12:24:56
The annual Australian Biotechnology Summit begins next week
Additional Resources
Newsletter Subscription
Australian Life Scientist Member Login
Multimedia Technology signs exclusive National distribution agreement with Freecom 2008-10-07 14:30:00+10
WD Unveils Affordable, High-Capacity Network Storage For Small Offices And Homes 2008-10-07 11:40:00+10
Multimedia Technology & EVERKI sign exclusive distribution agreement. 2008-10-06 14:34:00+10
ONCE A YEAR OPPORTUNITY TO SPEAK TO THE VENDORS! 2008-10-06 13:48:00+10
Virgin Mobile Australia music strategy appointment 2008-10-01 16:48:00+10
Sponsored Links
Subscribe to Australian Life Scientist
Australian Life Scientist is Australia's leading magazine for the life sciences sector. ALS is available free of charge to qualified persons working in the life sciences - register now for your free subscription.
